WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 13, 1292-1304. Review Article ISSN 2277–7105

A REVIEW ARTICLE ON RECENT ADVANCES ON CANCER CHEMOTHERAPY

***Diwan Samiya, Dr. Nidhi Chauhan, Mrs Mitali Patel, Khan Kaif, Bhavya Modi, Yogi Laxmi**

Laxminarayandev College of Pharmacy, Jay Ambe International School, besides, Narayan Kunj Vihar Society, Bholav, Bharuch, Gujarat 392012.

Article Received on 05 June 2026,
Article Revised on 25 June 2026,
Article Published on 01 July 2026

https://doi.org/10.5281/zenodo.21067781

***Corresponding Author**
Diwan Samiya

Laxminarayandev College of Pharmacy, Jay Ambe International School, besides, Narayan Kunj Vihar Society, Bholav, Bharuch, Gujarat 392012.

How to cite this Article: *Diwan Samiya, Dr. Nidhi Chauhan, Mrs Mitali Patel, Khan Kaif, Bhavya Modi, Yogi Laxmi (2026). A Review Article On Recent Advances On Cancer Chemotherapy. World Journal of Pharmaceutical Research, 15(13), 1292-1304.

ABSTRACT

Cancer remains one of the leading causes of death worldwide, and chemotherapy continues to play a vital role in its treatment. However, traditional chemotherapeutic agents are often associated with severe side effects, lack of selectivity, and the development of drug resistance. In recent years, significant advances have been made in cancer chemotherapy to improve efficacy, reduce toxicity, and enhance patient outcomes. This review highlights the latest developments in chemotherapy, including targeted therapies, immunotherapy, nanotechnology-based drug delivery systems, antibody-drug conjugates, and personalized medicine approaches. These innovations offer new hope in achieving better therapeutic responses while minimizing adverse effects. Despite these advancements, challenges such as high treatment costs, limited accessibility, and resistance mechanisms persist. Continued research and the active role of pharmacists are essential to optimize cancer chemotherapy and ensure its successful implementation in clinical practice.

KEYWORDS: Cancer chemotherapy, Targeted therapy, Immunotherapy, Personalized medicine, Drug resistance, Nanoparticle drug delivery, cyclin dependent kinase inhibitor.

1 INTRODUCTION[1,3]

Cancer is a diverse and complex disease that results from a series of molecular and genetic changes, leading to the uncontrolled multiplication of cells and abnormal tissue growth in

various parts of the body. Normally, cells follow a cycle of growth, aging, and programmed death, but cancer cells bypass this regulation. These malignant cells hijack nutrients, oxygen, and biological signals to promote their survival, often at the expense of healthy cells. They are also capable of evading the immune system and manipulating their surroundings to their benefit.

Several biological markers such as HE4, CEA, and osteopontin are now used to detect cancers at various stages. Over the years, numerous chemical and natural compounds have been developed to target cancer through different mechanisms, such as altering cellular metabolism, inducing apoptosis (programmed cell death), and interfering with DNA replication and repair.

The concept of chemotherapy emerged during World War II after it was discovered that mustard gas derivatives could damage lymphatic tissues. This led to the use of nitrogen mustard, the first chemotherapeutic agent, which showed temporary regression of tumours in patients. Chemotherapy functions by targeting fast-growing cancer cells, exploiting their vulnerability due to high metabolic stress. However, its non-selective nature often leads to significant side effects by harming normal, rapidly dividing cells as well.

Despite the challenges, chemotherapy continues to be one of the primary treatment options, especially for advanced cancers where surgery or radiation is not feasible. Over time, chemotherapy has expanded to include a variety of drug classes, such as alkylating agents, antimetabolites, and microtubule inhibitors, all of which act through different biological targets and mechanisms.



Figure 1 Schematic diagram showing different intrinsic and extrinsic biological/molecular

events potentiating the trans- formation of a normal cell to the cancer cell, while the lower part of this diagram showing different hallmarks of a transformed cancer cell. [1]



Figure 2 Schematic diagram showing the basic principles of chemotherapy (A), different classes of chemotherapeutic agents/ drugs (B), and immunotherapeutic mechanism(s) of targeting cancer cells (C). [1]

In recent years, progress in cancer research has introduced more sophisticated treatment strategies, such as targeted drug therapy, immunotherapy, and personalized medicine, which aim to reduce toxicity and improve outcomes by tailoring treatment to individual patients. This review highlights both traditional chemotherapeutic practices and emerging approaches that are redefining modern cancer therapy.

2 LIMITATIONS OF TRADITIONAL CHEMOTHERAPY[2]

While chemotherapy has been instrumental in treating various forms of cancer, it is not without significant limitations and challenges. The most prominent issue is its **non-selective mechanism of action**, which means it not only targets cancerous cells but also damages healthy, rapidly dividing cells such as those in the bone marrow, digestive tract, and hair follicles. This leads to a wide range of **side effects**, including fatigue, hair loss, nausea, vomiting, immune suppression, and increased risk of infection.

Chemotherapy drugs are typically administered at **high doses** to ensure maximum effectiveness, but this often results in **toxicity to normal tissues**. Such exposure can cause serious harm to a patient's physical and mental well-being, sometimes forcing discontinuation

of treatment. Additionally, chemotherapy can have long-term consequences, including organ damage and secondary cancers due to its mutagenic potential.

Another critical concern is **drug resistance**, which may develop after repeated or prolonged exposure to chemotherapeutic agents. Cancer cells can adapt through various mechanisms such as altering drug targets, increasing drug efflux, or repairing DNA damage, all of which reduce drug effectiveness. Once resistance develops, treatment becomes less effective and recurrence of the disease is more likely.

Moreover, **tumor heterogeneity** poses a significant barrier to successful chemotherapy. Within the same tumor, different populations of cancer cells may respond differently to treatment. This diversity complicates drug targeting and often results in incomplete eradication of the tumor, allowing resistant cells to survive and proliferate.

In many cases, chemotherapy is **palliative** rather than curative—its main goal is to slow tumor growth, relieve symptoms, and improve quality of life, rather than eliminate the disease completely. As a result, it is often used alongside other treatments such as surgery, radiation, or immunotherapy to improve outcomes.

Despite its drawbacks, chemotherapy remains a core component of cancer treatment, particularly in advanced or inoperable cases. However, the need for more **precise, less toxic, and more effective alternatives** has led to a growing emphasis on newer approaches like targeted therapy, immunotherapy, and personalized medicine.

In recent years, progress in cancer research has introduced more sophisticated treatment strategies, such as targeted drug therapy, immunotherapy, and personalized medicine, which aim to reduce toxicity and improve outcomes by tailoring treatment to individual patients. This review highlights both traditional chemotherapeutic practices and emerging approaches that are redefining modern cancer therapy.

3 RECENT ADVANCES IN CHEMOTHERAPY[3,8]

In response to the significant limitations of traditional chemotherapy, research has led to the development of advanced and more selective treatment strategies. These recent innovations aim to increase the effectiveness of cancer therapy while reducing toxicity and resistance.

One major advancement includes the development of targeted therapies, which are drugs

designed to act on specific molecular targets involved in cancer progression. Unlike conventional chemotherapy, these treatments affect cancer cells more precisely, sparing healthy cells and reducing side effects. Examples include tyrosine kinase inhibitors, PARP inhibitors, mTOR inhibitors, and angiogenesis blockers, all of which interfere with distinct cellular pathways essential for cancer cell survival.

3.1 IMMUNOTHERAPY

The discovery of immune checkpoint proteins such as PD-1, PD-L1, and CTLA-4 has significantly advanced the field of cancer immunotherapy. These checkpoint molecules regulate T-cell activity, playing a crucial role in maintaining immune balance by preventing excessive immune activation that could otherwise damage normal tissues. Their ability to modulate immune responses is essential for distinguishing between harmful and healthy cells. The clinical approval of antibodies targeting CTLA-4 and PD-1 has resulted in substantial improvements in outcomes for various cancers. These therapies have become integral to modern cancer treatment and are often used either alone or in combination with traditional therapies like chemotherapy and radiotherapy, achieving impressive therapeutic success across multiple tumor types. Immune checkpoint inhibitors (ICIs) enhance the body's immune defence against cancer by blocking specific receptors on T cells, thereby restoring and amplifying their anti-tumor activity. The U.S. Food and Drug Administration (FDA) has approved three major classes of ICIs: **PD-1 inhibitors** (including Nivolumab, Pembrolizumab, and Cemiplimab), **PD-L1 inhibitors** (such as Atezolizumab, Durvalumab, and Avelumab), and **CTLA-4 inhibitor** (Ipilimumab), all of which have demonstrated clinical effectiveness in treating several malignancies.

3.2 PERSONALIZED MEDICINE

Personalized medicine (PM) has emerged as a transformative approach in modern healthcare, offering a more precise alternative to conventional treatment methods. It focuses on analyzing a patient's individual medical history and biological profile to design custom medical therapies and diagnostic tools. This patient-centered strategy is reshaping how healthcare is delivered, enabling tailored interventions based on unique clinical and genetic information.

For many healthcare providers, this shift represents a significant advancement in predicting disease risk and implementing preventive strategies, including early diagnosis, customized therapies, and the use of targeted medications that address specific genetic variations. Because traditional diagnostic and treatment approaches are often generalized, they may not be equally

effective for all individuals, especially in complex diseases such as cancer. Personalized medicine addresses this limitation by offering individualized solutions grounded in a deep understanding of the patient's condition, disease stage, and genetic susceptibility.

Next-generation sequencing (NGS) plays a vital role in personalized oncology, enabling cost-effective and rapid analysis of tumor DNA. This technology helps identify specific mutations and genetic markers associated with different cancer types, allowing for targeted therapeutic interventions that are more likely to succeed. Additionally, personalized medicine can stratify patients into subgroups based on their likely response to a particular drug—whether synthetic or herbal—thus optimizing treatment outcomes and minimizing unnecessary side effects.

In summary, personalized medicine represents a forward-thinking and highly effective approach to managing cancer and other complex diseases by leveraging genetic insights to guide diagnosis, prevention, and treatment strategies.

3.3 TARGETED DRUG THERAPY

Targeted drug therapy is a modern approach to cancer treatment that focuses on specific molecules and signalling pathways essential for tumor growth and survival. Unlike conventional chemotherapy, which affects all rapidly dividing cells, targeted therapy acts selectively on cancer cells by interfering with molecular targets such as proteins, receptors, or genes that are uniquely altered in malignancies. This precision reduces damage to normal, healthy tissues and often results in fewer side effects.

The development of targeted therapies is based on a detailed understanding of cancer biology, including mutations, gene expression patterns, and tumor microenvironments. These drugs are designed to block the activity of oncogenes or to restore the function of tumor suppressor genes. Common molecular targets include receptor tyrosine kinases (e.g., EGFR, HER2), angiogenesis regulators (e.g., VEGF), and intracellular signaling pathways (e.g., PI3K/Akt, MAPK).

Several targeted therapies have received approval from the U.S. Food and Drug Administration (FDA) for various cancers. For example

- Imatinib targets the BCR-ABL fusion protein in chronic myeloid leukemia (CML).
- Trastuzumab binds to the HER2 receptor in HER2-positive breast cancer.
- Erlotinib and Gefitinib inhibit EGFR in non-small cell lung cancer (NSCLC).

- Bevacizumab blocks VEGF to inhibit tumor angiogenesis.

These drugs can be administered alone or in combination with chemotherapy, radiation, or immunotherapy to enhance treatment effectiveness. They are often used alongside diagnostic tools such as genetic profiling and biomarker testing to identify patients most likely to benefit from specific therapies—a key aspect of personalized medicine.

Despite their benefits, targeted therapies are not without challenges. Resistance may develop over time due to additional mutations or compensatory signalling pathways. Continuous research and combination therapy strategies are being explored to overcome these limitations and further improve patient outcomes.

In summary, targeted therapy represents a paradigm shift in oncology by offering more effective, personalized, and safer treatment options for patients with cancer.

3.4 CDK INHIBITORS[15,18]

Cyclin-dependent kinases (CDKs) are a family of serine-threonine kinases that regulate progression of the cell cycle. Dysregulation of the cyclin-CDK pathway is a common event in many cancers, leading to uncontrolled cellular proliferation. Therefore, CDKs have emerged as important therapeutic targets in modern cancer treatment.

Among the different CDK family members, CDK4 and CDK6 play a crucial role in regulating the G1-to-S phase transition of the cell cycle. Overactivation of the cyclin D–CDK4/6 pathway leads to phosphorylation of the retinoblastoma (Rb) protein, which subsequently activates E2F transcription factors and promotes DNA synthesis and tumor cell proliferation.

Recent advances in targeted therapy have led to the development of selective CDK4/6 inhibitors, such as Palbociclib, Ribociclib, and Abemaciclib, which are currently approved for the treatment of hormone receptor-positive metastatic breast cancer. These drugs inhibit CDK4/6 activity and suppress tumor cell proliferation by inducing cell-cycle arrest.

3.5 MECHANISM OF ACTION OF CDK INHIBITORS

CDK4/6 inhibitors exert their anticancer effect by blocking the cyclin D-CDK4/6 complex responsible for progression from the G1 phase to the S phase of the cell cycle.

Normally, the cyclin D-CDK4/6 complex phosphorylates the retinoblastoma (Rb) protein,

leading to release of E2F transcription factors that activate genes required for DNA replication and cell cycle progression. When CDK4/6 inhibitors are administered, phosphorylation of Rb is prevented, resulting in G1 cell-cycle arrest and inhibition of tumor cell proliferation.

This blockade of cell-cycle progression can lead to cellular senescence, reduced tumor growth, and in some cases apoptosis of cancer cells. Additionally, CDK4/6 inhibitors enhance the effectiveness of endocrine therapy when used in combination for hormone receptor-positive breast cancer.



Figure 3 Schematic diagram showing targeted cancer therapeutic approaches. (A) Model showing targeted drug delivery approach of anti-cancer drugs/chemical agents conjugated with receptor substrate specific to the cancer cell receptor. (B) Model showing the building of a personalized medicine approach based on omics data and drug response study targeting specific mutation/signature in individual patients for precision cancer therapeutics. (C) Model showing immunotherapeutic regime involving reprogramming of T-cells to target cancer cells by a chimeric antigen receptor for their application in cancer immunotherapy.[1]

3.6 ANTIMICROBIAL PEPTIDE

Antimicrobial peptides (AMPs), naturally occurring components of innate immunity, are emerging as a promising new class of anticancer agents. This review explores the potential of AMPs as a novel class of anticancer agents. AMPs, naturally occurring peptides with broad-spectrum antimicrobial activity, exhibit several characteristics that make them attractive candidates for cancer therapy, including selectivity for cancer cells, broad-spectrum activity, and immune modulatory effects. Analysis of a dataset of AMPs with anticancer activity reveals that their effectiveness is influenced by various structural properties, including net charge, length, Boman index, and hydrophobicity. These properties contribute to their ability to target and disrupt cancer cell membranes, interfere with intracellular processes, and modulate the immune response. The review highlights the promising potential of AMPs as a new frontier in cancer treatment, offering hope for more effective and less toxic therapies. AMPs demonstrate promising potential in cancer therapy through multiple mechanisms, including direct cytotoxicity, immune response modulation, and targeting of the tumor microenvironment, as evidenced by extensive preclinical studies in animal models showing tumor regression, metastasis inhibition, and improved survival rates. AMPs show significant potential as cancer therapeutics through their direct cytotoxicity, immune response modulation, and tumor microenvironment targeting, with promising results from preclinical studies and early-phase clinical trials. Future research should focus on optimizing AMP properties, developing novel delivery strategies, and exploring synergistic combination therapies to fully realize their potential as effective cancer treatments, while addressing challenges related to stability, delivery, and potential toxicity.

3.7 COMBINATION THERAPY[8,9]

Combination therapy involves using two or more therapeutic agents simultaneously or sequentially to treat cancer. The goal is to enhance therapeutic efficacy, reduce the chance of drug resistance, and minimize side effects by targeting multiple pathways or cellular mechanisms involved in cancer growth and survival.

1. **Multiple Pathway Targeting**

Cancer is a complex disease involving several genetic mutations and cellular signalling pathways. Using drugs that target **different molecular pathways** (e.g., EGFR, VEGF, mTOR, or immune checkpoints) ensures broader inhibition of tumor survival mechanisms. For example

- A chemotherapy drug may inhibit cell division.
- A targeted therapy may block a specific growth signal like HER2.

2. Overcoming Drug Resistance

Tumours often develop **resistance** to single-agent therapies. Combining drugs with different mechanisms of action can prevent or delay resistance by:

- Disrupting **compensatory survival pathways**
- Inhibiting **mutation-driven escape mechanisms**

Examples of Combination Regimens

- **FOLFOX** (5-fluorouracil + leucovorin + oxaliplatin) – colorectal cancer
- **CHOP** (cyclophosphamide + doxorubicin + vincristine + prednisone) – lymphoma
- **Nivolumab + Ipilimumab** – melanoma, NSCLC (dual checkpoint blockade)

4 FUTURE PROSPECTIVE[10,14]

Emerging clinical approaches increasingly emphasize that **combination therapy** holds strong potential as an effective strategy for managing various cancer types. These combination approaches often integrate chemotherapy with other advanced treatment modalities, such as **targeted drug delivery, immunotherapy, and personalized medicine**. This integration not only enhances overall treatment efficacy but may also improve the responsiveness of certain tumours that are otherwise less reactive to conventional therapies.

Among these strategies, **personalized combination therapies**—which are tailored to the molecular characteristics of individual tumor types—are showing particular promise. As we gain deeper insights into patient-specific tumor biology, there is a growing focus on developing individualized therapeutic regimens, which could lead to significantly improved clinical outcomes.

While chemotherapy continues to serve as a critical component of cancer treatment, its potential is being further amplified through its use in **combination regimens**. However, translating these integrated treatment strategies into consistent clinical success remains a challenge, highlighting the need for **continued research and clinical evaluation**.

In conclusion, although chemotherapy has contributed significantly to cancer care, there remains considerable room for improvement, especially concerning the **efficacy and safety** of existing treatment protocols. To fully realize the potential of combination therapies, **more**

comprehensive investigations, including the **rational design of drugs**, **robust clinical trials**, and **careful patient stratification**, are essential. These efforts will be crucial in achieving broader and more effective application of chemotherapeutic strategies in clinical practice.

Chemotherapy remains one of the most widely studied and clinically validated approaches in cancer treatment. This report reviews the current landscape of chemotherapeutic strategies and highlights various drugs and agents currently in clinical use, illustrating how the field has progressed over time. It also explores the therapeutic potential and draggability of different cancer types.

Recent developments in drug discovery focus on modifying existing drugs to create **new derivatives** that offer **greater effectiveness and reduced toxicity**. Additionally, there is growing interest in **natural compounds** derived from microbes, plants, and other natural sources, as these agents show promising potential in activating stress response pathways that trigger cancer cell death.

Natural compounds used in chemotherapy offer several advantages over their synthetic counterparts, such as **lower cytotoxicity**, **reduced cost**, and **simpler methods of extraction and production**. Given these benefits, increasing attention is being paid to integrating natural agents into treatment regimens.

Looking ahead, a critical aspect of advancing chemotherapy will be the **ability to minimize treatment-related toxicity**, which will significantly influence the effectiveness and acceptability of future chemotherapeutic protocols.

5 CONCLUSION

Cancer chemotherapy has undergone a significant transformation in recent decades, evolving from traditional cytotoxic agents to more precise and effective therapeutic strategies. While conventional chemotherapy remains a cornerstone of cancer treatment, it is often associated with serious side effects and the development of drug resistance. Recent advances—including targeted drug therapy, immunotherapy, nanotechnology-based drug delivery systems, and personalized medicine—have revolutionized the way cancer is treated, offering increased efficacy, reduced toxicity, and improved patient outcomes.

Moreover, the integration of **combination therapies** has shown promising potential in enhancing treatment response and overcoming resistance mechanisms. These combinations,

especially when guided by molecular profiling and individualized patient characteristics, represent the future of oncology care.

Despite these advancements, challenges remain in terms of accessibility, cost, treatment resistance, and toxicity. Therefore, ongoing research, clinical trials, and the development of innovative therapeutic approaches are essential to further refine and optimize chemotherapeutic regimens.

In summary, the future of cancer chemotherapy lies in **precision, personalization, and integration** with novel therapies. With continued scientific efforts and clinical innovations, these advances hold the promise of making cancer therapy more effective, safer, and tailored to the unique needs of each patient.

6 REFERENCES

1. Anand, U., Dey, A., Singh Chandel, A. K., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & Pérez de la Lastra, J. M. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases, 2023; 10: 1367–1401.
2. Pfirschke C, Siwicki M, Liao HW, Pittet MJ. Tumor microenvironment: no effector T cells without dendritic cells. Cancer Cell., 2017; 31(5): 614e615.
3. V. T., Jr., & Chu, E. A history of cancer chemotherapy. Cancer Research, 2008; 68(21): 8643–8653.
4. O'Neill, V. J., & Twelves, C. J. Oral cancer treatment: Developments in chemotherapy and beyond. British Journal of Cancer, 2002; 87(9): 933–937.
5. Kalal, B. S., Upadhya, D., & Pai, V. R. Chemotherapy: Does it have a future in the era of targeted therapy? Journal of Clinical and Diagnostic Research, 2017; 11(7): 01–05.
6. Longley, D. B., & Johnston, P. G. Molecular mechanisms of drug resistance. The Journal of Pathology, 2005; 205(2): 275–292.
7. Zhang, H., & Chen, J. Current status and future perspectives of cancer immunotherapy. Journal of Haematology & Oncology, 2020; 13: 45.
8. Pellizzari, G., Hoskin, V., Crespo, M., & Muthuswamy, S. K. Cancer organoids for precision medicine: Status, challenges and future perspectives. Cancer Cell, 2021; 39(9): 1207–1221.
9. Larkin, J., ChiarionSileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., ... &

Wolchok, J. D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 2015; 373(1): 23–34.

10. Wang, M., & Kaufman, R. J. The impact of the unfolded protein response on human disease. The Journal of Cell Biology, 2014; 197(7): 857–867.
11. Gottesman, M. M. Mechanisms of cancer drug resistance. Annual Review of Medicine, 2002; 53: 615–627.
12. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 2023; 73(1): 17–48.
13. Chabner, B. A., & Roberts, T. G. Chemotherapy and the war on cancer. Nature Reviews Cancer, 2005; 5(1): 65–72.
14. Porzi M, Mazzaro G. CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. Eur. J Med. Chem., 2020; 195: 112278.
15. Shafie N, Moghaddas S, Nikanfar S, et al. Biological effects and molecular mechanisms of Abemaciclib on breast cancer. Biol. Effects 2023; DOI: 10.22034/bej. 2023.WO12.
16. Nazari H, Ehsani Z, Ghaffari S, et al. Inhibiting CDKs in breast cancer: Palbociclib, Ribociclib, Abemaciclib. Biol. Effects. 2023; DOI: 10.22034/bej. 2023.WO15.
17. Wang Y. Breaking cancer's momentum: CDK4/6 inhibitors and the promise of combination therapy. Cancer Discov 2023; DOI: 10.22034/bej. 2023.WO14.